非诺贝特对非酒精性脂肪性肝病小鼠模型肠道菌群多样性的影响

张丹; 周波; 邓溢; 文玉; 吕俊衍; 王金香; 耿坐涛; 罗粟风; 应昀晏; 文代艳; 施春晶; 普光宇; 姜鑫; 马岚青

doi:10.3969/j.issn.1001-5256.2020.04.024

非诺贝特对非酒精性脂肪性肝病小鼠模型肠道菌群多样性的影响

DOI: 10.3969/j.issn.1001-5256.2020.04.024

1. 昆明医科大学第一附属医院消化内科
2. 昆明医科大学基础医学院

基金项目:

国家自然科学基金项目(81760108,81560099)；云南省重点项目(2018FA039)；云南省教育厅科学研究基金项目(2019Y0353)；昆明医科大学研究生创新基金(2019S023)；

详细信息

中图分类号: R575.5;R-332
计量
- 文章访问数: 1383
- HTML全文浏览量: 69
- PDF下载量: 226
- 被引次数: 0
出版历程
- 收稿日期: 2019-11-17
- 出版日期: 2020-04-20

Effect of fenofibrate on the diversity of intestinal flora in a mouse model of nonalcoholic fatty liver disease

Department of Gastroenterology,The First Affiliated Hospital of Kunming Medical University

Research funding:

摘要

摘要: 目的探讨非诺贝特对非酒精性脂肪性肝病（NAFLD）小鼠肠道菌群多样性的影响。方法将30只小鼠随机分为3组,正常组（n=10）、高脂组（n=10）、非诺贝特治疗组（n=10）,高脂组与非诺贝特治疗组给予高脂饮食干预14周,正常组给予普通饮食14周。在满10周开始对非诺贝特治疗组给予非诺贝特灌胃治疗并继续给予高脂饮食4周,全程监测小鼠体质量变化; 14周后收集3组粪便用于高通量测序16S rRNA分析菌群的多样性及差异;并收集肝组织进行HE染色及油红O染色观察脂肪变性情况。多组间比较采用单因素方差分析,进一步两两比较采用LSD-t检验。结果干预10周后,非诺贝特治疗组较高脂组体质量明显减轻（P <0. 05）。HE染色及油红O染色显示非诺贝特治疗组脂肪沉积较高脂组明显减少。非诺贝特治疗组与高脂组肠道菌群存在明显差异,而与正常组肠道菌群具有相似性,非诺贝特治疗组拟杆菌门、疣微菌门、Faecalibaculum、Muribaculaceaenorank、阿克曼菌属丰度明显升高,厚壁菌门、放线菌门、梭菌属、Turicibacter、双歧杆菌属丰度降低。结论拟杆菌门、疣...
- 非酒精性脂肪性肝病 /
- 非诺贝特 /
- 肠道菌群 /
- 小鼠,近交C57BL
Abstract: Objective To investigate the effect of fenofibrate on the diversity of intestinal flora in mice with nonalcoholic fatty liver disease( NAFLD). Methods A total of 30 mice were randomly divided into normal group,high-fat group,and fenofibrate treatment group,with10 mice in each group. The mice in the high-fat group and the fenofibrate treatment group were given high-fat diet intervention for 14 weeks,and those in the normal group were given normal diet for 14 weeks. After 10 weeks of dietary intervention,the mice in the fenofibrate treatment group were given fenofibrate by gavage and high-fat diet for another 4 weeks,and the change in body weight was monitored during the whole process. Fecal samples were collected after 14 weeks,and high-throughput sequencing 16 S rRNA was used to investigate the diversity and difference of intestinal flora. Liver tissue samples were collected,and HE staining and oil red O staining were performed to observe the degree of steatosis. A one-way analysis of variance was used for comparison between multiple groups,and the least significant difference t-test was used for further comparison between two groups. Results After 10 weeks of intervention,the fenofibrate treatment group had a significantly lower body weight than the high-fat group( P < 0. 05). The results of HE staining and oil red O staining showed that the fenofibrate treatment group had a significantly lower degree of fat deposition than the high-fat group. There was a significant difference in intestinal flora between the fenofibrate treatment group and the high-fat group,while there was no significant difference in intestinal flora between the fenofibrate treatment group and the normal group. The fenofibrate treatment group had significant increases in the abundance of Bacteroidetes,Verrucomicrobia,Faecalibaculum,Muribaculaceae＿norank,and Akkermansia and significant reductions in the abundance of Firmicutes,Actinobacteria,Clostridium,Turicibacter,and Bifidobacterium. Conclusion The increases in the abundance of Bacteroidetes and Verrucomicrobia and the reductions in the abundance of Firmicutes and Actinobacteria suggest that fenofibrate may have positive significance in the treatment of NAFLD.
- nonalcoholic fatty liver disease /
- fenofibrate /
- intestinal flora /
- mice,inbred C57BL

HTML全文

参考文献(26)

[1] JIANG YZ,NIE HM,WANG R. Research advances in the pathogenesis of nonalcoholic fatty liver disease[J]. J Clin Hepatol,2019,35(11):2588-2591.(in Chinese)姜煜资，聂红明，汪蓉．非酒精性脂肪性肝病的发病机制[J]．临床肝胆病杂志，2019,35(11):2588-2591.

[2] FRIEDMAN SL,NEUSCHWANDER BA,MARY R,et al. Mechanisms of NAFLD development and therapeutic strategies[J].Nat Med,2018,24(7):908-922.

[3] PIMPIN L,CORTEZ-PINTO H,NEGRO F,et al. Burden of liver disease in Europe:Epidemiology and analysis of risk factors to identify prevention policies[J]. J Hepatol,2018,69(3):718-738.

[4] ARAU'JO AR,ROSSO N,BEDOGNI G,et al. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis:What we need in the future[J]. Liver Int,2018,38(Suppl 1):47-51.

[5] CORTE CD,MAZZOTTA AR,NOBILI V. Fatty liver disease and obesity in youth[J]. Curr Opin Endocrinol Diabetes Obes,2016,23(1):66-71.

[6] GUREEV AP,SHMATKOVA ML,BASHMAKOV VY,et al. The effect of fenofibrate on expression of genes involved in fatty acids beta-oxidation and associated free-radical processes[J]. Biomed Khim,2016,10(1):70-74.

[7] LEFEBVRE P. Sorting out the roles of PPARαin energy metabolism and vascular homeostasis[J]. J Clin Invest,2006,116(3):571-580.

[8] HUANG FF,WANG JJ,YU FM,et al. Protective effect of meretrix meretrix oligopeptides on high-fat-diet-induced nonalcoholic fatty liver disease in mice[J]. Mar Drugs,2018,16(2):39-55.

[9] ZHANG D,MA LQ. Research advances in the role and mechanism of peroxisome proliferator-activated receptor alpha in liver diseases[J]. J Clin Hepatol,2019,35(10):2351-2354.(in Chinese)张丹，马岚青．过氧化物酶体增殖激活受体α在肝脏疾病中的作用及机制[J]．临床肝胆病杂志，2019,35(10):2351-2354.

[10] MONTAGNER A,POLIZZI A,FOUCHE E,et al. Original article:Liver PPARαis crucial for whole-body fatty acid homeostasis and is protective against NAFLD[J]. Gut,2016,65(7):1202-1214.

[11] YAO FF,JIA RP,HUANG H,et al. Effect of Lactobacillus paracasei N1115 and fructooligosaccharides in nonalcoholic fatty liver disease[J]. Arch Med Sci,2019,15(5):1336-1334.

[12] LU S,ZHANG T,GU W,et al. Volatile oil of amomum villosum inhibits nonalcoholic fatty liver disease via the gut-liver axis[J]. Bio Med Res Int,2018,7(19):35-48.

[13] LI F,SUN G,WANG ZK,et al. Characteristics of fecal microbiota in non-alcoholic fatty liver disease patients[J]. Sci China Life Sci,2018,61(7):770-778.

[14] QUAN M,XING HC. Research progress on intestinal flora and chronic liver diseases[J/CD]. Chin J Liver Dis(Electronic Version),2019,11(3):26-30.(in Chinese)全敏，邢卉春．肠道菌群与慢性肝病相关研究进展[J/CD]．中国肝脏病杂志(电子版)，2019,11(3):26-30.

[15] MA JL,ZHOU QH,LI HK. Gut microbiota and nonalcoholic fatty liver disease:Insights on mechanisms and therapy[J].Nutrients,2017,9(10):e1124.

[16] YU X,WANG WJ,JIN JY,et al. Linggui Zhugan decoction combined with probiotics in the treatment of nonalcoholic fatty liver disease[J]. J Changchun Univ Chin Med,2019,35(5):891-894.(in Chinese)喻晓，王雯婕，金嘉悦，等．苓桂术甘汤联合益生菌治疗非酒精性脂肪肝[J]．长春中医药大学学报，2019,35(5):891-894.

[17] LIU HL,LIU MH,FU XQ,et al. Astaxanthin prevents alcoholic fatty liver disease by modulating mouse gut microbiota[J].Nutrients,2018,10(9):1298-1315.

[18] YOUNGMI J,INYOUNG K,MOHAMED M,et al. Effect of Kombucha on gut-microbiota in mouse having non-alcoholic fatty liver disease[J]. Food Sci Biotechnol,2018,28(1):261-267.

[19] GUO J,CHEN YY,YE F. Therapeutic efects of fenofibrate on nonalcoholic faty liver disease in vitro and related mechanism[J]. Acta Med Univ Sci Technol Huazhong,2017,46(3):265-270.(in Chinese)郭骏，陈玉媛，叶枫．非诺贝特缓解非酒精性脂肪性肝病的体外机制研究[J]．华中科技大学学报:医学版，2017,46(3):265-270.

[20] ZHANG N,LU Y,SHEN X,et al. Fenofibrate treatment attenuated chronic endoplasmic reticulum stress in the liver of nonalcoholic fatty liver disease mice[J]. Pharmacology,2015,95(3-4):173-180.

[21] HOJYO S,FUKADA T. Zinc transporters and signaling in physiology and pathogenesis[J]. Arch Biochem Biophys,2016,611:43-50.

[22] NAN J,YANG SX. Research advances in non-statin drugs for lipid regulation[J]. Chin J Geriatr Heart Brain Vess Dis,2016,18(6):655-658.(in Chinese)南京，杨水祥．非他汀类调脂药物的研究进展[J]．中华老年心脑血管病杂志，2016,18(6):655-658.

[23] SUK KT,KIM DJ. Gut microbiota:Novel therapeutic target for nonalcoholic fatty liver disease[J]. Expert Rev Gastroenterol Hepatol,2019,13(3):193-204.

[24] LIU CC,LI W,WANG LY. Relationship between gut microbiota and non-alcoholic fatty liver disease[J]. Chin J Gastroenterol Hepatol,2017,26(10):1103-1106.(in Chinese)刘晨晨，李稳，王凌云．肠道菌群与非酒精性脂肪性肝病关系的研究进展[J]．胃肠病学和肝病学杂志，2017,26(10):1103-1106.

[25] LU M,TANG YC,LI M,et al. Co-administration of cholesterol-lowering probiotics and anthraquinone from cassia obtusifolia l. ameliorate non-alcoholic fatty liver[J]. PLo S One,2015,10(9):e0138078.

[26] LIU BH,ZHANG J,SUN P,et al. Raw bowl tea(tuocha)polyphenol prevention of nonalcoholic fatty liver disease by regulating intestinal function in mice[J]. Biomolecules,2019,9(435):1-20.

施引文献

资源附件(0)

访问统计